 Your new post is loading...
Your new post is loading...
Scoop.it!
The multiple sclerosis risk gene IL22RA2 contributes to a more severe murine ... 
No comment yet.
Sign up to comment
Scoop.it!
Natalizumab was a breakthrough in MS therapy. However, side effects of this monoclonal antibody limit its use. The risk/benefit ratios of new biologicals in MS therapy are not yet clear. High-yield process daclizumab might qualify as first-line MS therapy, unless hepatotoxicity becomes a relevant safety concern. Alemtuzumab has been approved for MS therapy in Europe but will be reserved for selected patients with highly active disease due to frequent induction of potentially dangerous secondary autoimmune phenomena. Ocrelizumab will likely also be licensed as a second-line therapy in highly active MS. Neutralizing antibodies to interleukin (IL)-17A and blocking antibodies to leucine rich repeat and Ig domain containing 1 might be the most interesting upcoming new antibodies as both offer a new and pathophysiologically relevant approach in MS therapy.
Via Krishan Maggon
Krishan Maggon 's curator insight,
July 8, 2014 6:25 PM
Keywordsalemtuzumab, antibody, anti-IL-17A, anti-LINGO1, daclizumab, Medi-551, MOR103, multiple sclerosis, ocrelizumab, ofatumumab, opinion, tabalumab, tocilizumab
Scoop.it!
The development of Parkinson's disease in a mouse model was blocked by treatment with monoclonal antibodies directed at alpha-synuclein, the main protein component of the Lewy bodies and Lewy neurites that characterize the disease. (Antisynuclein...
Scoop.it!
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients... http://t.co/NTIH4LwkNl #jimmTCB
Scoop.it!
![The Diagnosis of Autoimmune Encephalopathies, Dementias, and Epilepsies [Communiqué] | NeuroImmunology | Scoop.it](https://img.scoop.it/Wt6DTw6a7JxP2_TOJLXSATl72eJkfbmt4t8yenImKBVvK0kTmF0xjctABnaLJIm9)
Many disorders of the central nervous system previously considered neurodegenerative and untreatable are now recognized as having an autoimmune cause.
Scoop.it!
PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Scoop.it!
PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Scoop.it!
Research from JAMA Neurology — Cross-Sectional and Longitudinal Relationships Between Cerebrospinal Fluid Biomarkers and Cognitive Function in People Without Cognitive Impairment From Across the Adult Life Span (Cross-Sectional and Longitudinal...
Scoop.it!
Immunotherapeutic approaches, such as dendritic cell (DC) vaccination, have emerged as promising strategies in the treatment of glioblastoma. Despite their promise, however, the absence of objective biomarkers and/or immunological monitoring techniques to assess the clinical efficacy of immunotherapy still remains a primary limitation. To address this, we sought to identify a functional biomarker for anti-tumor immune responsiveness associated with extended survival in glioblastoma patients undergoing DC vaccination. Via Krishan Maggon
Krishan Maggon 's curator insight,
June 13, 2014 3:07 AM
open access full text Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients Richard G Everson1†, Richard M Jin1†, Xiaoyan Wang2, Michael Safaee1, Rudi Scharnweber1, Dominique N Lisiero15, Horacio Soto1, Linda M Liau134 and Robert M Prins1345* *Corresponding author: Robert M Prins rprins@mednet.ucla.edu † Equal contributorsAuthor Affiliations 1Departments of Neurosurgery, University of California Los Angeles, Los Angeles, CA 90095, USA 2Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA 3Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095, USA 4Brain Research Institute, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA 90095, USA 5Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA For all author emails, please log on. Journal for ImmunoTherapy of Cancer 2014, 2:10 doi:10.1186/2051-1426-2-10 The electronic version of this article is the complete one and can be found online at:http://www.immunotherapyofcancer.org/content/2/1/10
Scoop.it!
Circulating anti-filamin C autoantibody as a potential serum biomarker for low ...
Gilbert C FAURE's insight:
low grade gliomas
Scoop.it!
CSL Behring Announces the 2014 Interlaken Leadership Awards Recipient
Gilbert C FAURE's insight:
Guillain Barre therapy with IVIGs
Scoop.it!
Alpha Labs supply Neuroimmunology anti-glycolipid antibody assays and anti-ganglioside assays for both diagnostic and research purposes
Gilbert C FAURE's insight:
buhlmann and more
Scoop.it!
Background:Increased concentrations of matrix metalloproteinases (MMP) in cerebrospinal fluid are part of the host response in bacterial meningitis (BM).
|
Scoop.it!
Free Access to the 2013 Top 10 Downloads from Clinical and Experimental Neuroimmunology - read now! #Neurology
Scoop.it!
Human embryonic stem cells are a potentially viable treatment option for multiple sclerosis. (Human Stem Cells Effectively Treat Multiple Sclerosis in Mice Models: Embryonic stem cells are a potentially v...
Scoop.it!
Metronomic cyclophosphamide given on an intermittent, 6-day repeating schedule, but not on an exposure dose-equivalent daily schedule, activates an anti-tumor innate immune response that leads to major regression of ...
Scoop.it!
Multiple sclerosis (MS) is an autoimmune disease in which inflammatory lesions lead to tissue injury in the brain and/or spinal cord.
Scoop.it!
The Guardian Terry Pratchett forced to cancel appearance by Alzheimer's The Guardian Terry Pratchett, who announced his diagnosis with early onset Alzheimer's seven years ago, has pulled out of a Discworld convention later this summer, saying "the...
Scoop.it!
CNS demyelinating disorder with mixed features of neuromyelitis optica and multiple sclerosis in HIV-1 infection. ... http://t.co/FJcJDVxZQ4
Scoop.it!
Neuroimmunology and Neuroinflammation,China (Welcome to Neuroimmunology and Neuroinflammation: a new open access journal for neuroscience http://t.co/aTwSCyQbZq)...
Scoop.it!
Surg Neurol Int, Official publication of Surgical Neurology International (Good Tutorials: Basic principles of immunology http://t.co/vfAauLZjbh Part 2: Innate brain immunity
Société Francaise d'Immunologie's comment,
June 28, 2014 4:05 AM
Our knowledge concerning the workings of the immune system has evolved considerably over the past 20 years, with great strides being made as regard to complex interactions and repertoire of effector reactions under a host of conditions. Many of our previous understandings have been challenged, especially concerning tumor immunology and autoimmunity. Also of critical importance is our understanding of how the immune system terminates its attacks and the mechanisms used to regulate the balance between proinflammatory and antiinflammatory mechanisms, so as to prevent excessive immune bystander damage. I will discuss in part I the basic physiology of innate immune function and the immune systems reactions to invasion by microorganisms.
Scoop.it!
Retrospective studies show that natalizumab modifies oligoclonal immunoglobulin (IgG) bands (OCBs) in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients. In this study, we prospectively analyzed both serum ...
Scoop.it!
From
alzres
Activation of the complement system, a pivotal part of inflammation, occurs at very early stages in the AD brain. Therefore, CSF levels of complement proteins that could be linked to cognitive and structural changes in AD may ...
Scoop.it!
Recent studies suggested that the chemokine CXCL13 in the cerebrospinal fluid (CSF) is a biomarker for active LNB. Also, CSF neopterin-level determination has been used to assess the degree of neuroinflammation in a ...
Scoop.it!
Recent paper: Genome-wide CNV analysis of cerebrospinal fluid #tumor cells & corresponding archival primary tumors http://t.co/n3W8RTBYXQ
|
